Gerhard P.. Schwall

Gerhard P.. Schwall

Auto-generated profile, based on publicly available information

Gerhard P.. Schwall

ProteoSys AG, Mainz, Germany

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2000 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
GSGerhard P. Schwall
Gerhard P. Schwall
RSRichard Safford
Richard Safford
RWRoger J. Westcott
Roger J. Westcott
RJRoger Jeffcoat
Roger Jeffcoat
ATAkash Tayal
Akash Tayal
SJStephen A. Jobling
Stephen A. Jobling

1 April 1999 in The Plant Journal
Verified
Journal Article
Open access
PDF file
SJStephen A.. Jobling
Stephen A.. Jobling
GSGerhard P.. Schwall
Gerhard P.. Schwall
RWRoger J.. Westcott
Roger J.. Westcott
CSChristopher M.. Sidebottom
Christopher M.. Sidebottom
MDMartine Debet
Martine Debet
RSRichard Safford
Richard Safford
Summary: Full length cDNAs encoding a second starch branching enzyme (SBE A) isoform have been isolated from potato tubers. The predicted protein has a molecular mass of 101 kDa including a transit peptide of 48 amino acids. Multiple forms of the SBE A gene exist which differ mainly in the length of a polyglutamic acid repeat at the C‐terminus of the protein. Expression of the mature protein in Escherichia coli demonstrates that the gene encodes an active SBE. Northern analysis demonstrates that SBE A mRNA is expressed at very low levels in tubers but is the predominant isoform in leaves. This expression pattern was confirmed by Western analysis using isoform specific polyclonal antibodies raised against E. coli expressed SBE A. SBE A protein is found predominantly in the soluble phase of tuber extracts, indicating a stromal location within the plastid. Transgenic potato plants expressing an antisense SBE A RNA were generated in which almost complete reductions in SBE A were observed. SBE activity in the leaves of these plants was severely reduced, but tuber activity was largely unaffected. Even so, the composition and structure of tuber starch from these plants was greatly altered. The proportion of linear chains was not significantly increased but the average chain length of amylopectin was greater, resulting in an increase in apparent amylose content as judged by iodine binding. In addition, the starch had much higher levels of phosphorous.

1 March 2002 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
SJStephen A. Jobling
Stephen A. Jobling
RWRoger J. Westcott
Roger J. Westcott
ATAkash Tayal
Akash Tayal
RJRoger Jeffcoat
Roger Jeffcoat
GSGerhard P. Schwall
Gerhard P. Schwall

15 October 2008 in Breast Cancer Research
Verified
Journal Article
Open access
HNHans Neubauer
Hans Neubauer
SCSusan E Clare
Susan E Clare
WWWojciech Wozny
Wojciech Wozny
GSGerhard P Schwall
Gerhard P Schwall
SPSlobodan Poznanović
Slobodan Poznanović
MCMichael Cahill
Michael Cahill
Introduction: Breast tumors lacking the estrogen receptor-α (ER-α) have increased incidence of resistance to therapy and poorer clinical prognosis. Methods: Whole tissue sections from 16 cryopreserved breast cancer tumors that were either positive or negative for the ER (eight ER positive and eight ER negative) were differentially analyzed by multiplex imaging of two-dimensional PAGE gels using 54 cm isoelectric focusing. Differentially detected spots of Progesterone Receptor Membrane Component 1 (PGRMC1) were shown to differ in phosphorylation status by differential two dimensional polyacrylamide gel electrophoresis of phosphatase-treated tumor proteins. Site directed mutagenesis was used to create putative phosphorylation site point mutants in PGRMC1. Stable transfectants of these mutants in MCF7 cells were assayed for their survival after oxidative stress, and for AKT kinase phosphorylation. Immune fluorescence using anti-PGRMC1 monoclonal antibody 5G7 was performed on breast cancer tissue microarrays. Results: Proteins significantly differentially abundant between estrogen receptor negative and estrogen receptor positive tumors at the 0.1% level were consistent with published profiles, suggesting an altered keratin pool, and increased inflammation and wound responses in estrogen receptor negative tumors. Two of three spots of PGRMC1 were more abundant in estrogen receptor negative tumors. Phosphatase treatment of breast tumor proteins indicated that the PGRMC1 isoforms differed in their phosphorylation status. Simultaneous mutation of PGRMC1 serine-56 and serine-181 fully abrogated the sensitivity of stably transfected MCF7 breast cancer cells to peroxide-induced cell death. Immune fluorescence revealed that PGRMC1 was primarily expressed in ER-negative basal epithelial cells of mammary ductules. Even in advanced tumors, high levels of ER or PGRMC1 were almost mutually exclusive in individual cells. In five out of five examined ductal in situ breast cancers of comedo type, PGRMC1 was expressed in glucose transporter 1 negative or positive poorly oxygenated cells surrounding the necrotic core, surrounded by a more distal halo of ER-positive cells. Conclusions: PGRMC1 phosphorylation may be involved in the clinical differences that underpin breast tumors of differing ER status.

1 January 2009 in Journal of Urology
Verified
Journal Article
Closed access
MSMartin Schostak
Martin Schostak
GSGerhard P. Schwall
Gerhard P. Schwall
SPSlobodan Poznanović
Slobodan Poznanović
KGKarlfried Groebe
Karlfried Groebe
MMMarkus Müller
Markus Müller
ASAndré Schrattenholz
André Schrattenholz
In prostate cancer cases the early diagnosis of tumors carrying a high risk of progression is of the utmost importance. There is an urgent clinical need to avoid unnecessary biopsies and subsequent overtreatment. We validated annexin A3 as a diagnostic marker for prostatic disease in typical clinical populations and relevant segments, such as patients with a negative digital rectal examination and low prostate specific antigen. We performed a blinded clinical study (ClinicalTrials.gov Identifier NCT00400894) from September 2005 to January 2007 in 591 patients who were continuously recruited from 4 European urological clinics. Urine was obtained directly after digital rectal examination and the annexin A3 concentration in urine was quantified by Western blot. Statistical analysis included combinations of annexin A3 with total, percent free, complexed and percent complexed prostate specific antigen. Combined readouts of prostate specific antigen and urinary annexin A3 were superior to all others with an area under the ROC curve of 0.82 for a total prostate specific antigen range of 2 to 6 ng/ml, 0.83 for a total prostate specific antigen range of 4 to 10 ng/ml and 0.81 in all patients. The best performing prostate specific antigen derivative was percent free prostate specific antigen with an area under the ROC curve of 0.68 for a total prostate specific antigen range of 2 to 6 ng/ml, 0.72 for a total prostate specific antigen range of 4 to 10 ng/ml and 0.73 in all patients. Annexin A3 has an inverse relationship to cancer and, therefore, its specificity was much better than that of prostate specific antigen. Annexin A3 quantification in urine provides a novel noninvasive biomarker with high specificity. Annexin A3 is complementary to prostate specific antigen or to any other cancer marker. It has a huge potential to avoid unnecessary biopsies with a particular strength in the clinically relevant large group of patients who have a negative digital rectal examination and prostate specific antigen in the lower range of values (2 to 10 ng/ml).

1 December 2008 in European Urology
Verified
Journal Article
Closed access
JKJens Köllermann
Jens Köllermann
TSThorsten Schlomm
Thorsten Schlomm
HBHolger Bang
Holger Bang
GSGerhard P. Schwall
Gerhard P. Schwall
CEChristoph von Eichel-Streiber
Christoph von Eichel-Streiber
ASAndré Schrattenholz
André Schrattenholz